Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic Atrophy
PRIME Designation Granted Based on Phase 2 ARCHER Trial Results, which Showed Meaningful Preservation of Visual Function in Patients with Geographic Atrophy ANX007 is the First Therapeutic...
San Francisco United States Sheryl Seapy Chelcie Lister Annexon Inc American Academy Of Ophthalmology
Source: marketscreener.com